(0.34%) 5 117.14 points
(0.33%) 38 365 points
(0.38%) 15 989 points
(-0.97%) $83.04
(5.25%) $2.02
(0.35%) $2 355.30
(0.48%) $27.67
(4.09%) $959.85
(-0.26%) $0.932
(-0.44%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
@ $1.391
発行日: 15 2月 2024 @ 01:10
リターン: 2.39%
前回のシグナル: 2月 14 - 05:52
前回のシグナル:
リターン: 4.59 %
Live Chart Being Loaded With Signals
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies...
Stats | |
---|---|
本日の出来高 | 164 241 |
平均出来高 | 984 632 |
時価総額 | 354.51M |
EPS | $0 ( 2024-03-19 ) |
次の収益日 | ( $-0.0900 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.65 |
ATR14 | $0.00300 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Thomasian Harry Jr. | Buy | 135 714 | Common Stock |
2024-04-05 | Thomasian Harry Jr. | Sell | 67 389 | Common Stock |
2024-04-05 | Thomasian Harry Jr. | Buy | 135 714 | Restricted Stock Units |
2024-04-05 | Thomasian Harry Jr. | Sell | 135 714 | Restricted Stock Units |
2024-04-05 | Perez Jeffrey Thomas | Buy | 142 857 | Common Stock |
INSIDER POWER |
---|
34.54 |
Last 99 transactions |
Buy: 8 317 118 | Sell: 3 939 504 |
ボリューム 相関
Precigen Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Precigen Inc 相関 - 通貨/商品
Precigen Inc 財務諸表
Annual | 2023 |
収益: | $6.23M |
総利益: | $-4.74M (-76.18 %) |
EPS: | $-0.390 |
FY | 2023 |
収益: | $6.23M |
総利益: | $-4.74M (-76.18 %) |
EPS: | $-0.390 |
FY | 2022 |
収益: | $26.91M |
総利益: | $20.57M (76.44 %) |
EPS: | $-0.400 |
FY | 2021 |
収益: | $103.87M |
総利益: | $45.49M (43.79 %) |
EPS: | $-0.470 |
Financial Reports:
No articles found.
Precigen Inc
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。